TGen, Oncoholdings to develop anti-cancer agents

Under the agreement, TD2 – a subsidiary of Translational Genomics Research Institute (TGen), will be the exclusive development partner for Oncoholdings’ oncology portfolio.

The company plans to develop about 15 early-stage drugs over the next three years.

TD2 president Stephen Gately said the company is eager to put the scientific assets of Oncoholdings on a precise path, moving their drug compounds safely and effectively to benefit cancer patients.

Oncoholdings is a US-based pharmaceutical company focused on acquiring and developing anti-cancer agents.

TD2 provides its expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients.